2-Methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Catalog No. :
ACRBPC169
CAS No. :
1421324-79-9
Molecular Formula :
C13H20BNO3
Molecular Weight :
249.12

IUPAC Name:2-methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2-Methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%$101.00Login to see priceInquiryInquiry
5g98%$277.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
IUPAC Name2-methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
MDL No.MFCD18086152
Molecular FormulaC13H20BNO3
Molecular Weight249.12
SMILESCC1=CC=C(B(O2)OC(C)(C)C2(C)C)C(OC)=N1
InChI KeyCSTSNPMFFHPFHT-UHFFFAOYSA-N
SynonymPyridine, 2-methoxy-6-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1421324-79-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACRBPC169 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. ACDIOY931 route compound structure diagram
    ACDIOY931717843-47-5 In Stock
  4. Then
  5. ACRBPC169 route product structure diagram
    ACRBPC1691421324-79-9
Inquiry

2. ACRBPC169 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRBPC169 route product structure diagram
    ACRBPC1691421324-79-9
Inquiry

Comments (0)